The combination of -arrestin mediated cardioprotection, with increased -arrestin-mediated contractility, should translate into both short and longer-term benefits in the setting of acute heart failure
," stated Dr.
The first is a composite endpoint for acute heart failure
which assesses a patient's symptoms and persistent or worsening heart failure within the first 48 hours after treatment initiation.
Prominent Sponsors 30 Top Companies Participating in Acute Heart Failure
Therapeutics Clinical Trials 31 Prominent Drugs 32 Latest Clinical Trials News on Acute Heart Failure
33 Jul 28, 2014: Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 33 Clinical Trial Profiles 34 Clinical Trial Overview of Top Companies 34 Novartis AG 34 Clinical Trial Overview of Novartis AG 34 Nile Therapeutics, Inc.
Acute Heart Failure
Therapeutics under Development by Companies
The findings also reveal that all of the emerging acute heart failure
therapies are set to surpass many of the current therapies in terms of both efficacy and safety.
This most recent study demonstrates that the pharmacologic effects of TRV027 are preserved when administered with the diuretic furosemide, which is currently first-line therapy for acute heart failure
However, owing to its advantages in efficacy and safety and tolerability, Novartis's relaxin will displace furosemide and will earn Decision Resources' proprietary clinical gold-standard status for acute heart failure
in 2019, following its launch for the indication in 2014.
6, 2012 /PRNewswire/ -- The Phase III RELAX-AHF study has shown that investigational RLX030 (serelaxin) improved symptoms and reduced deaths by one-third at the end of six months in patients with acute heart failure
Table 3: World Historic Review for Acute Heart Failure
Acute Heart Failure
Pipeline Review, Q4 2010, provides an overview of the Acute Heart Failure
Therapy Industry : Global Acute Heart Failure
(AHF) Therapeutics Industry
A recently published clinical study, "Prognostic Significance of the Occurrence of Acute Heart Failure
After Successful Primary Percutaneous Coronary Intervention" by L.
a commercial product indicated for the treatment of acute heart failure
In preclinical studies, this biased ligand has demonstrated a unique range of biological effects that will be beneficial for patients with acute heart failure
During her 12 year tenure at Scios, she was the clinical lead for Natrecor, a commercial product indicated for the treatment of acute heart failure